Abstract:
Objective This work aimed to evaluate the efficiency and acute toxicities of recombinant human endostatin (Endostar)combined with chemotherapy in metastatic nasopharyngeal carcinoma (NPC).
Methods Thirty metastatic NPC patients were treated with Endostar in combination with chemotherapy. The chemotherapeutic regimen consisted of cisplatin and fluorouracil, or cisplatin and gemcitabine. Endastar was intravenously given at a dosage of 7.5 mg·m-2·day-1 for 14 days. The treatment outcomes were evaluated according to the RESIST criteria. The National Cancer Institute–Common Toxicity Criteria–AE3.0 (NCI-CTC-AE 3.0) was used to evaluate the acute toxicities.
Results All 30 patients completed the plan. Among them, complete remission was found in 4 patients, partial remission in 22, stable disease in 3, and progressed disease in 1. Adverse events Grade 3 and above included granulocytopenia and thrombocytopenia. Leftventricular diastolic dysfunction occurred in 1 patient. All adverse events were treated and relieved.
Conclusion Endostar combined with chemotherapy was efficient and safe for metastatic NPC. Further studies are needed to verify the long-term effects.